A new bioRxiv preprint posted June 10 found maternal cells in children’s brains at striking rates, and those cells didn’t just sit there. In 26 of 37 mother-child pairs, or 70%, the researchers detected cells with the mothers' DNA hiding among millions of cells. The cells showed up across multiple brain regions and, crucially, persisted for decades, even in samples from people in their 90s.

The twist is what those maternal cells became once they arrived. Using single nucleus RNA sequencing, the team found the maternal microchimeric cells had transformed into several kinds of functional brain cells, including neurons, oligodendrocytes, astrocytes, microglia, and endothelial cells. That means this is not just a DNA curiosity from pregnancy biology. It is tissue-level evidence, using cutting-edge methods, showing the mother-fetus cell exchange can leave an imprint on the adult brain.

This phenomenon is part of “microchimerism,” the broader idea that a mother and fetus exchange cells during pregnancy. Researchers have long known microchimerism can show up in blood and in infancy. But as Amy Boddy, co-director of the Microchimerism, Human Health and Evolution Project at the University of California, Santa Barbara, told Live Science, previous work mostly found maternal microchimerism in infancy and in blood samples. “What’s exciting here is that it’s tissue, not blood; it’s real human data, not an animal model; and the methods are cutting-edge,” she said. And because the study’s approach finds rare cells in real human brain tissue, it pushes the field closer to the “normal process of mammalian biology” view Boddy described.

So how did the researchers pull it off? The study needed human brain tissue where both parents' DNA could be compared, which is notoriously hard to get. To solve that, a team led by Sami Kanaan, a staff scientist at the Fred Hutchinson Cancer Center in Seattle, analyzed brain tissue surgically removed from dozens of children with severe epilepsy as part of their treatment. The age range was wide, from 28 days to 19 years at the time of surgery. The mothers provided DNA samples through cheek swabs. Then Kanaan’s team used quantitative PCR to identify and count maternal cells among millions of cells in the children’s brains.

The results were uneven at the individual level, which matters for interpretation. Each sample had, on average, about 2.2 maternal cells per 100,000, but one hippocampus sample had 459 maternal cells per 100,000. Meanwhile, 11 children showed no evidence of maternal DNA in their brains. Boddy cautioned that this prevalence is probably underestimated because of “the limits of detecting rare cells at low frequency with this method.” In other words: the absence of detection may not equal true absence.

The study also flagged a pattern around birth order. Being a firstborn child seemed to increase the odds of having maternal cells in the brain. Among the children who carried their mother’s cells, 14 were firstborns and 12 were later-born. Among those who didn’t have these cells, only one was a firstborn and 10 were later-born. While the preprint has not been peer-reviewed yet, this is the kind of signal that future, larger datasets would be expected to test, especially given the method’s known detection limits.

To move from “where” these cells are to “what they do,” the researchers used single nucleus RNA sequencing. This technique reveals what a cell is doing by showing which genes within the cells are switched on. The maternal microchimeric cells were distributed into multiple brain cell types, including neurons; oligodendrocytes, which produce the protective sheath around neurons; astrocytes, which support many brain functions and help fuel neurons; microglia, the brain’s immune cells; and endothelial cells, which line blood vessels. The researchers suspect these cells were originally leukocytes and stem cells and were transferred to the fetus via the placenta or during pregnancy or breastfeeding.

The preprint then asked the bigger question: do these findings show up outside severe epilepsy? The researchers examined brain autopsy data from 29 individuals with no known neurodevelopmental conditions, ages ranging from 22 weeks of gestation to 40 years. They also analyzed brain tissue from three men in their late 80s and early 90s without known brain conditions, originally collected as part of an Alzheimer's disease study. In total, foreign cells were found in 25 of 32 people, about 78%, including in the brain of a man in his 90s. The researchers suspect these foreign cells are maternal, but they could not confirm because they did not have DNA from the mothers. The team noted the foreign cells could have come from a twin; an older sibling; a past pregnancy, miscarriage or abortion (in females); or rarely from a maternal grandmother.

Notably, the “type” of maternal microchimeric cells appeared to shift with age. In younger brains, they most often became a specific kind of neuron, a layer 2/3 neuron. In older brains, maternal cells were more likely to be microglia. The authors frame this as an unanswered question: given the diversity of roles, it would be interesting to know whether cell function reflects their origin, for example mother versus an older biological sibling versus a maternal grandmother, said Dr. Sing Sing Way of Cincinnati Children's Hospital Medical Center, who was not involved in the study.

For executives and investors watching biotech and health research, the business-relevant point is less “maternal DNA is in brains” and more “the tools are getting good enough to measure it.” Boddy said microchimeric cells appear to be common and suggested that understanding their function could be important for understanding healthy brain development. At the same time, Way said the study pushes the boundaries of previous research, but future studies would benefit from larger and more uniform datasets, including more brain biopsies, more cells per sample, sampling at different ages, and sampling similar brain regions across individuals.

Even with those caveats, this preprint changes the conversation from a low-resolution curiosity to a tissue-level, cell-type-level phenomenon that can persist for decades. That has second-order implications for how researchers interpret “normal” brain biology, and for how clinicians and scientists might think about cell origins when they see unexpected cell populations. And because the evidence touches real human tissue and multiple brain regions, the question becomes not whether microchimerism exists, but what it is doing there, and whether it is quietly helping shape outcomes that we currently attribute to other factors.